Assessing pneumococcal meningitis association with viral respiratory infections and antibiotics: insights from

Lulla Opatowski1, Emmanuelle Varon, Claire Dupont

  • 1Unité de Pharmaco-épidémiologie et Maladies Infectieuses PhEMI, Institut Pasteur, 75015 Paris, France. lulla.opatowski@pasteur.fr

Insights

Respiratory viruses and antibiotic use significantly impact Streptococcus pneumoniae meningitis incidence. Preventing viral infections may reduce invasive pneumococcal disease.

Area of Science:

  • Epidemiology
  • Mathematical Modeling
  • Infectious Disease Dynamics

Background:

  • Pneumococcus is a major cause of antibiotic-resistant bacterial meningitis globally.
  • Understanding factors influencing pneumococcal infection and antibiotic susceptibility is crucial for prevention.
  • The role of respiratory viruses in pneumococcal epidemiology is poorly understood.

Purpose of the Study:

  • To investigate the relationship between Streptococcus pneumoniae meningitis incidence (SPMI), acute viral respiratory infections (AVRIs), and antibiotic exposure.
  • To develop and analyze a mathematical model for virus-bacteria interactions.
  • To assess the impact of AVRIs on pneumococcal transmissibility and pathogenicity.

Main Methods:

  • Analysis of French time series data for SPMI, AVRI, and penicillin consumption (2001-2004).
  • Development of four distinct virus-bacteria interaction submodels.
  • Statistical analysis and model simulations to evaluate hypothetical relationships.

Main Results:

  • SPMI showed a significant increase following AVRI incidence.
  • Higher antibiotic prescription rates correlated with decreased SPMI.
  • Model simulations indicated AVRIs increase pneumococcal transmissibility (up to 1.3-fold) and pathogenicity (up to threefold).
  • Resistant pneumococcal strains causing meningitis exhibited diminished epidemic fitness (0.97).

Conclusions:

  • AVRIs and antibiotic use are strong drivers of SPMI trends.
  • Vaccination against respiratory viruses may offer indirect benefits in reducing invasive pneumococcal infections.
  • Mathematical modeling provides insights into complex pathogen dynamics.

Related Concept Videos

Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps: